American biotech events get most of the attention, but Europe has a dense and distinctive conference scene of its own, and for companies with European investors, partners, or ambitions, the transatlantic calendar is not optional. The European events tend to be a little smaller, a little more relationship-driven, and heavily oriented toward cross-border dealmaking. Here are the ones worth the flight in 2026, grouped by what they are actually for.
The partnering anchors
Europe’s biggest biotech gatherings are, like their American cousins, built around one-to-one partnering.
- BIO-Europe (November 9 to 11, 2026, Cologne) is the largest life-science partnering conference in Europe, produced by the EBD Group in collaboration with BIO. It draws thousands of biopharma and finance leaders and runs a partnering system comparable in spirit to BIO International, making it the continent’s premier autumn dealmaking event.
- BIO-Europe Spring is its springtime counterpart, moving to a different European city each year and offering a second major partnering window earlier in the calendar.
If your goal is business development with European pharma and biotech, these two are the anchors to build a European strategy around.
Investor and financing events
For fundraising and investor relationships, a different set of events matters.
- LSX World Congress in London is the flagship event for European life-science financing, gathering biotech and medtech executives, investors, and dealmakers. For a company whose cap table is, or should be, European, LSX is close to essential.
- Bio€quity Europe is a long-running, higher-signal gathering of European CEOs and investors, smaller and more focused than the mega-events, and valued precisely for that intimacy.
- Sachs Associates and other specialist organizers run a series of European biotech investor forums throughout the year that are worth tracking if financing is your focus.
The national and regional showcases
Europe’s strength is its cluster of national ecosystems, each with a flagship event that concentrates the local industry and its international visitors.
- Swiss Biotech Day in Basel showcases one of the world’s densest life-science hubs and draws a strongly international crowd.
- Nordic Life Science Days is the largest partnering event in the Nordic region, a fast-growing biotech corner with an outsized record of building companies.
- Country-level events across the UK, Germany, France, the Netherlands, and beyond gather regional ecosystems and are worth attending if you have a specific interest in that market.
These regional showcases are especially useful if you are looking to establish a presence in a particular country, tap into local investors, or connect with the research institutions and talent that cluster around each hub.
Scientific congresses on European soil
Europe also hosts world-leading scientific meetings that function as major data catalysts. The ESMO Congress is the continent’s premier oncology event and a genuine market-moving catalyst on par with the American oncology meetings, while the European Hematology Association congress plays the same role for blood disorders. Modality-specific meetings, in advanced therapies, biologics, and more, round out a scientific calendar that rivals anything in the US. If your work is scientific rather than commercial, these are where European data lands.
How to choose, if you can only do a few
Match the event to your goal, exactly as you would in the US. For partnering and BD, BIO-Europe is the anchor. For fundraising, LSX World Congress and the investor forums. For establishing a national presence, the relevant country showcase. For scientific data, ESMO, EHA, or the modality congress in your area. The common European mistake is the same as the American one: attending broadly and preparing narrowly. Two well-worked European events beat five where you drift.
A note on the transatlantic strategy
Many companies now run a deliberately transatlantic conference plan, using the American events for scale and the US investor base, and the European events for cross-border partnering and access to Europe’s public and private capital. If you are building toward a European partnership, a listing on a European exchange, or simply a more geographically diversified investor base, seeding those relationships at European events a year or two ahead pays off. The relationships that close a European deal in 2027 are often first made at a European conference in 2026.
Plan the whole picture
Practical logistics that trip up US attendees
American companies attending European events for the first time run into a handful of avoidable snags. Timing is the first: the European calendar interleaves with the US one, so plan the whole year together rather than treating a European trip as an afterthought bolted onto an already full schedule. Geography is the second: Europe’s biotech hubs are spread across many countries and cities, and the temptation to string several events into one exhausting trip should be weighed against the value of being sharp for the meetings that matter. There is also the matter of cross-border travel logistics, which take more planning than a domestic US trip and should be sorted well in advance for anyone who needs them. Culturally, European partnering tends to be a little more relationship-driven and less transactional than its American counterpart, so patience and genuine relationship-building often pay off more than a hard pitch. And there is a strategic dimension worth internalizing: if you are attending European events, it is usually because you want European partners, investors, or market access, so come with a clear European narrative, why your company matters to this region, which local partners or investors you are targeting, and what you can offer them, rather than simply importing your US pitch unchanged. The companies that get the most from Europe treat it as its own ecosystem with its own logic, not as a satellite of the American scene, and they plan the practical details, the travel, the timing, the targeting, with the same care they would give a domestic flagship event.
The bottom line on Europe
Europe rewards the companies that treat it as a genuine strategic region rather than a side trip. If your investor base is or should be European, LSX and the investor forums earn their place. If you are hunting cross-border partnerships, BIO-Europe is the anchor. If you want to plant a flag in a specific national ecosystem, the country showcases are the fastest way in. And if your work is scientific, the European congresses rival anything elsewhere. The one habit that separates the companies that get value from Europe from those that waste the trip is intentionality: knowing exactly why you are crossing the Atlantic, who you need to meet, and what you are offering them. Do that, and Europe becomes a powerful second engine for partnering and capital. Treat it as an afterthought, and it becomes an expensive detour.
One more angle: medtech and digital health
This guide focuses on biopharma, but Europe also hosts strong medtech and digital-health gatherings worth knowing if that is your world. Events across the continent bring together device makers, health-tech founders, hospitals, and the investors who fund them, and they follow the same logic as the biopharma calendar: pick the one or two matched to your goals rather than attending broadly. If your company sits at the intersection of biology and software, a growing space, it is worth scanning both the biopharma and the digital-health European calendars, because the right room for you may not be the obvious biotech flagship. As with everything in Europe, the payoff comes from choosing deliberately and arriving with a clear reason to be there.
Europe is one region in a global calendar, and the smartest planning looks at all of it together rather than treating the American and European events as separate worlds. The BioMed Nexus conferences directory lets you filter every major 2026 event, European and otherwise, by category and region, so you can build a coherent transatlantic calendar, and the daily brief keeps you current on the European deals and financings that tell you which relationships are worth pursuing.
Frequently asked questions
What is the biggest biotech conference in Europe?
BIO-Europe, held November 9 to 11, 2026 in Cologne, is the largest life-science partnering conference in Europe. Its springtime counterpart, BIO-Europe Spring, provides a second major partnering window earlier in the year in a different European city.
Which European biotech conference is best for fundraising?
LSX World Congress in London is the flagship event for European life-science financing, gathering executives, investors and dealmakers. Bio€quity Europe and specialist investor forums are strong complements, especially for companies building a European investor base.
Are European biotech conferences worth attending for US companies?
Yes, for US companies pursuing European partnerships, capital, or market entry. European events emphasize cross-border dealmaking and access to European public and private investors. Many companies run a transatlantic plan, using US events for scale and European events for cross-border partnering.
